Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/13—Amines
  • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/1605—Excipients; Inactive ingredients
  • A61K9/1629—Organic macromolecular compounds
  • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
  • A61K9/1605—Excipients; Inactive ingredients
  • A61K9/1629—Organic macromolecular compounds
  • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
  • A61P25/16—Anti-Parkinson drugs

Definitions

• a formulation of rasagiline mesylate is approved for treating Parkinson's disease either as monotherapy or as an adjunct with other treatments. See, e.g. AZTLECT®, Physicians' Desk Reference 2009 (PRD, 63 th Edition).
• AZILECT* is indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease as initial monotherapy and as adjunct therapy to levodopa.
• Rasagiline the active ingredient of AZILECT ® , is rapidly absorbed, reaching peak plasma concentration (Cmax) in approximately 1 hour.
• Cmax peak plasma concentration
• the absolute bioavailability of rasagiline is about 36%.
• the subject invention provides a solid dispersion of at least one polymeric pharmaceutical excipient and rasagiline or a pharmaceutically acceptable salt thereof.
• the subject invention also provides a pharmaceutical composition comprising the solid dispersion described herein.
• the subject invention further provides a process for making the solid dispersion described herein, comprising:
• the subject invention yet further provides a process for making the solid dispersion described herein, comprising:
• FIG. 1 Cyclic Differential Scanning Calorimetry (DSC) thermogram of Rasagiline citrate, sample size 3.43 mg, 20°C/min.
• Figure 2 Modulated Differential Scanning Calorimetry (MDSC) thermogram of
• Rasagiline citrate sample size 4,00 mg, 2°C/min.
• the subject invention provides a solid dispersion of at least one polymeric pharmaceutical excipient and rasagiline or a pharmaceutically acceptable salt thereof.
• the at least one polymeric pharmaceutical excipient is a water soluble polymeric pharmaceutical excipient.
• the pharmaceutically acceptable salt of rasagiline is rasagiline citrate.
• the rasagiline citrate is mono-rasagiline citrate.
• the at least one polymeric pharmaceutical excipient is polyvinylpyrrolidone, hydroxypropyl methylcellulose, hydroxypropyl metbylcellulose acetate succinate, or hydroxypropyl methylcellulose phthalate.
• the at least one polymeric pharmaceutical excipient is a co-polymer.
• the co-polymer is polyvinylpyrrolidone- vinyl acetate or methacrylic acid-ethyl acrylate.
• the co-polymer is methacrylic acid-ethyl acrylate.
• T g of the solid dispersion is at least 20°C higher than that of rasagiline or a pharmaceutically acceptable salt thereof.
• the subject invention also provides a pharmaceutical composition comprising the solid dispersion described herein.
• the subject invention further provides a process for making the solid dispersion of rasagiline citrate described herein, comprising:
• the subject invention further provides a process for making the solid dispersion of rasagiline citrate described herein, comprising:
• the pharmaceutically acceptable salt of rasagiline is rasagiline citrate.
• the rasagiline citrate is mono-rasagiline citrate.
• the solvent is methanol, ethanol, acetone, dichloromethane, dioxane and water, or a mixture of at least two thereof.
• step b) is performed at a temperature of between about 55°C and 80°C by rotary evaporation.
• the solvent is removed by lyophilization.
• the subject invention yet further provides a process for making the solid dispersion of rasagiline citrate described herein, comprising:
• the subject invention yet further provides a process for making the solid dispersion of rasagiline citrate described herein, comprising:
• the pharmaceutically acceptable salt of rasagiline is rasagiline citrate.
• the rasagiline citrate is mono- rasagiline citrate.
• step b) is performed by dry milling the mixture.
• step b) is performed by wet milling the mixture with a solvent.
• the solvent is methanol or acetone.
• step b) is performed at a temperature below 0°C.
• step b) is performed at a temperature below -10°C.
• step b) is performed at a temperature below -25°C.
• step b) is performed at a temperature below -50°C.
• step b) is performed at a temperature below -100°C.
• step b) is performed at a temperature below -150°C.
• the subject invention yet further provides a method of treating a human subject afflicted with Parkinson's disease comprising administering to the human subject an amount of the pharmaceutical composition of claim 8, effective to treat the human subject.
• any range disclosed herein it is meant that all hundredth, tenth and integer unit amounts within the range are specifically disclosed as part of the invention.
• 0.01 mg to 50 mg means that 0.02, 0.03 ... 0.09; 0.1, 0.2 ... 0.9; and 1, 2 ... 49 mg unit amounts are included as embodiments of this invention.
• Citric acid is a weak organic acid, and is triprotic. Therefore, the rasagiline citrate described herein may exist in mono-, di- or tri-rasagiline citrate form or a mixture thereof.
• an example of an immediate release formulation of rasagiline is an AZILECT® Tablet containing rasagiline mesylate.
• a polymer is a large molecule composed of repeating structural units typically connected by covalent chemical bonds.
• a "pharmaceutically acceptable" carrier or excipient is one that is suitable for use with humans and/or animals without undue adverse side effects (such as toxicity, irritation, and allergic response) commensurate with a reasonable benefit/risk ratio.
• a "pharmaceutically acceptable salt" of rasagiline includes citrate, tannate, malate, mesylate, maleate, fumarate, tartrate, esylate, p-toluenesulfonate, benzoate, acetate, phosphate and sulfate salts.
• the free base can be reacted with the desired acids in the presence of a suitable solvent by conventional methods.
• Rasagiline can also be used in its free base form. A process of manufacture of the rasagiline free base is described in PCT publication WO 2008/076348, the contents of which are hereby incorporated by reference.
• an "isolated" compound is a compound that has been separated from the crude reaction mixture in which it formed by an affirmative act of isolation.
• the act of isolation necessarily involves separating the compound from the other known components of the crude reaction mixture, with some impurities, unknown side products and residual amounts of the other known components of the crude reaction mixture permitted to remain. Purification is an example of an affirmative act of isolation.
• composition that is "free" of a chemical entity means that the composition contains, if at all, an amount of the chemical entity which cannot be avoided following an affirmative act intended to separate the chemical entity and the composition.
• a "glass transition temperature (7 ⁇ )" of a solid is the temperature where the solid goes from a rigid state to a flexible state.
• T g a polymer undergoes a phase transition from a hard, glass-like state to a flexible, rubber-like state.
• the T g temperature values listed herein were determined based upon half-height of the step change or "S" shape curve seen in DSC data.
• a polymer is a large molecule composed of repeating structural units typically connected by covalent chemical bonds.
• a "solid dispersion” is a drug-containing pharmaceutical bulk substance in which the drug is dispersed in a pharmaceutical excipient such as a polymer, a co-polymer, or a mixture thereof.
• a pharmaceutical excipient such as a polymer, a co-polymer, or a mixture thereof.
• Specific examples of pharmaceutically acceptable carriers and excipients that may be used to formulate oral dosage forms of the present invention are described, e.g., in U.S. Patent No. 6,126,968 to Peskin et al., issued Oct. 3, 2000.
• the pharmaceutical dosage forms may be prepared as medicaments to be administered orally, parenterally, rectally or transdermally.
• Suitable forms for oral administration include tablets, compressed or coated pills, dragees, sachets, hard or soft gelatin capsules, sublingual tablets, syrups and suspensions; for parenteral administration the invention provides ampoules or vials that include an aqueous or non-aqueous solution or emulsion; for rectal administration the invention provides suppositories with hydrophilic or hydrophobic vehicles; for topical application as ointments; and for transdermal delivery the invention provides suitable delivery systems as known in the art.
• Tablets may contain suitable binders, lubricants, disintegrating agents, coloring agents, flavoring agents, flow-inducing agents, melting agents, stabilizing agents, solubilizing agents, antioxidants, buffering agent, chelating agents, fillers and plasticizers.
• the active drug component can be combined with an oral, non-toxic, pharmaceutically acceptable, inert carrier such as gelatin, agar, starch, methyl cellulose, dicalcium phosphate, calcium sulfate, mannitol, sorbitol, microcrystalline cellulose and the like.
• Suitable binders include starch, gelatin, natural sugars such as corn starch, natural and synthetic gums such as acacia, tragacanth, or sodium alginate, povidone, carboxymethylcellulose, polyethylene glycol, waxes, and the like.
• Antioxidants include ascorbic acid, fumaric acid, citric acid, malic acid, gallic acid and its salts and esters, butylated hydroxyanisole, editic acid.
• Lubricants used in these dosage forms include sodium oleate, sodium stearate, sodium benzoate, sodium acetate, stearic acid, sodium stearyl fumarate, talc and the like.
• Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum, croscarmellose sodium, sodium starch glycolate and the like, suitable plasticizers include triacetin, triethyl citrate, dibutyl sebacate, polyethylene glycol and the like.
• One type of oral dosage forms of the present invention relates to delayed release formulations.
• Such formulations may be comprised of an acid resistant excipient which prevents the dosage form or parts thereof from contacting the acidic environment of the stomach.
• the acid resistant excipient may coat the rasagiline in the form of an enteric coated tablet, capsule, or gelatin capsule.
• Enteric coating in the context of this invention, is a coating which prevents the dissolution of an active ingredient in the stomach.
• Another type of oral dosage forms of the present invention relates to fast disintegrating formulations which provide a means to avoid the absorption of rasagiline in the stomach, and to eliminate the need for swallowing tablets, by absorption of rasagiline into the body before reaching the stomach.
• Such absorption of rasagiline can be accomplished by contact with the buccal, sublingual, pharyngeal and/or esophageal mucous membranes.
• the fast disintegrating formulations were designed to rapidly disperse within the mouth to allow maximum contact of rasagiline with the buccal, sublingual, pharyngeal and or esophageal mucous membranes.
• Transdermal patches are medicated adhesive patches placed on the skin to deliver a time- released dose of medication through the skin and into the bloodstream.
• a wide variety of pharmaceuticals can be delivered through transdermal patches. Some pharmaceuticals must be combined with other substances, for example alcohol, to increase their ability to penetrate the skin.
• Transdermal patches have several important components, including a liner to protect the patch during storage, the drug, adhesive, a membrane (to control release of the drug from the reservoir), and a backing to protect the patch from the outer environment.
• the two most common types of transdermal patches are matrix and reservoir types. (Wikipedia; and Remington, The Science and Practice of Pharmacy, 20* Edition, 2000)
• a drug is combined with a non-volatile, inert liquid, such as mineral oil, whereas in matrix type patches a drug is dispersed in a lipophilic or hydrophilic polymer matrix such as acrylic or vinylic polymers.
• Adhesive polymers such as polyisobutylene, are used to hold the patch in place on the skin.
• transdermal drug-delivery The major limitation to transdermal drug-delivery is the intrinsic barrier property of the skin. Penetration enhancers are often added to transdermal drug formulations in order to disrupt the skin surface and cause faster drug delivery. Typical penetration enhancers include high-boiling alcohols, diols, fatty acid esters, oleic acid and glyceride-based solvents, and are commonly added at a concentration of one to 20 percent (w/w). (Melinda Hopp, "Developing Custom Adhesive Systems for Transdermal Drug Delivery Products," Drug Delivery)
• the present invention provides pharmaceutical dosage forms useful for treating a condition selected from the group consisting of: Parkinson's disease (PD), brain ischemia, stroke, head trauma injury, spinal trauma injury, neurotrauma, neurodegenerative disease, neurotoxic injury, nerve damage, dementia, Alzheimer's type dementia, senile dementia, depression, memory disorders, hyperactive syndrome, attention deficit disorder, Multiple Sclerosis (MS), schizophrenia, affective illness, Amyotrophic Lateral Sclerosis, Restless Legs Syndrome (RLS), hearing loss, Multiple System Atrophy (MSA), Glucoma, modifying Parkinson's disease, and Progressive Supranuclear Palsy (PSP), but with a reduced risk of peripheral MAO inhibition that is typically associated with administration of rasagiline with known oral dosage forms.
• PD Parkinson's disease
• MS Multiple Sclerosis
• RLS Restless Legs Syndrome
• MSA Multiple System Atrophy
• Glucoma modifying Parkinson's disease
• PPP Progressive Supranuclear Palsy
• a conventional method for the manufacture of a solid dispersion relates to a fusion process which is characterized by melting a drug substance and a polymeric pharmaceutical excipient together at elevated temperature and, then, cooling the melt to solidify.
• Another conventional method for the manufacture of a solid dispersion relates to a solvent process which is characterized by dissolving a drug substance and a polymeric pharmaceutical excipient in an appropriate solvent and, then, removing the solvent.
• Additional method for the manufacture of a solid dispersion relates to mixing a drug substance and a polymeric pharmaceutical excipient through milling.
• phase-separated dispersion will exhibit two T g values, whereas a molecular dispersion will exhibit a single T g .
• the subject invention is also intended to include all isotopes of atoms occurring on the compounds disclosed herein. Isotopes include those atoms having the same atomic number but different mass numbers.
• isotopes of hydrogen include tritium and deuterium.
• isotopes of carbon include C-13 and C-14.
• any notation of a carbon in structures throughout this application when used without further notation, are intended to represent all isotopes of carbon, such as 12 C, "C, or 14 C.
• any compounds containing 13 C or l4 C may specifically have the structure of any of the compounds disclosed herein.
• any notation of a hydrogen in structures throughout this application when used without further notation, are intended to represent all isotopes of hydrogen, such as ⁇ , 2 H, or 3 H.
• any compounds containing 2 H or 3 H may specifically have the structure of any of the compounds disclosed herein.
• Isotopically-labeled compounds can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the Examples disclosed herein using an appropriate isotopically-labeled reagents in place of the non-labeled reagents employed.
• a solid dispersion screen was carried out using rasagiline citrate and pharmaceutical excipients of polymers.
• Dispersions were prepared using several techniques including rotary evaporation from solution, cryogrinding dry components and lyophilization. Samples were analyzed by modulated Differential Scanning Calorimetry (DSC) to determine glass transition temperatures (T g ). A slight excess of citric acid was used in most dispersions i.e. 0.7: 1 mol of rasagiline: citric acid.
• DSC Differential Scanning Calorimetry
• HSM hotstage microscopy
• DSC differential scanning calorimetry
• Rasagiline excipient weight ratio listed in parentheses.
• RE rotary evaporation.
• rasagiline citrate was formed in-situ by combining rasagiline free base, excipient, and citric acid in the preparation of solid dispersion of rasagiline citrate.
• the solid dispersion of rasagiline citrate can be prepared by obtaining rasagiline citrate salt first.
• the rasagiline citrate can be obtained by reacting rasagiline free base with citric acid in the presence of a suitable solvent by conventional methods, e.g. the process described in Example 1.
• the rasagiline citrate obtained can then be mixed with the excipient listed in Table 2 to prepare the solid dispersion of rasagiline citrate by the rotary evaporation as described in Example 2.
• the rasagiline citrate obtained can also be mixed with the excipient listed in Table 3 to prepare the solid dispersion of rasagiline citrate by dry milling, wet milling, or cryo-grinding as described in Example 3.
• the rasagiline citrate obtained can further be mixed with the excipient listed in Table 4 to prepare the solid dispersion of rasagiline citrate by lyophilization as described in Example 4.
• T g of mono- rasagiline citrate was ⁇ 17°C by DSC.
• Most of the solid dispersions of rasagiline citrate prepared appeared to be phase-separated by MDSC.
• T g of some of the solid dispersions of rasagiline citrate prepared was not observed due to decomposition of rasagiline at elevated temperatures.
• Dispersions containing PVP K.90 and PVP-VA have shown the largest increase in T g with high polymer loadings but both deliquesced when stressed under high relative humidity for 1 day.
• T g can be impacted by technique used to generate dispersions
• dispersions were prepared by different methods. For most polymers, little difference in T g was noted with different methods of preparation. However, for HPMC-P an increase in T g of ⁇ 20°C was observed for a lyophilized sample compared with a sample prepared by rotary evaporation.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Epidemiology (AREA)
• Neurosurgery (AREA)
• Biomedical Technology (AREA)
• Neurology (AREA)
• Inorganic Chemistry (AREA)
• Psychology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Medicinal Preparation (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Priority Applications (5)

Applications Claiming Priority (2)

Publications (2)

Family

ID=45530490

Family Applications (1)

Country Status (7)

Cited By (2)

Families Citing this family (15)

Citations (2)

Family Cites Families (37)

• 2011
  • 2011-07-27 AU AU2011282716A patent/AU2011282716A1/en not_active Abandoned
  • 2011-07-27 RU RU2013108256/15A patent/RU2013108256A/ru not_active Application Discontinuation
  • 2011-07-27 JP JP2013521947A patent/JP2013537530A/ja not_active Withdrawn
  • 2011-07-27 EP EP11813128.3A patent/EP2598136A4/en not_active Withdrawn
  • 2011-07-27 WO PCT/US2011/045569 patent/WO2012015946A1/en not_active Ceased
  • 2011-07-27 CA CA2806737A patent/CA2806737A1/en not_active Abandoned
  • 2011-07-27 US US13/192,082 patent/US8691872B2/en not_active Expired - Fee Related
• 2014
  • 2014-03-10 US US14/203,209 patent/US20140194510A1/en not_active Abandoned

Patent Citations (2)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events